Introduction
An antibody-drug conjugate (ADC) consists of a tumor-targeting monoclonal antibody (mAb) and a potent cytotoxic agent, connected by a peptide linker. In general, ADCs exert antitumor effects by selective delivery of cytotoxic agents into tumor tissues. Based on clinical results, ADCs are currently considered to be promising agents for cancer therapy [1] [2] [3] [4] . However, several issues must be resolved in order to achieve favorable clinical outcomes with ADCs, especially when treating solid tumors. Delivery of agents to cancer cells is more complicated for solid tumors than for hematological cancers. In particular, for treatment of a solid tumor, an ADC must have a high stability and a long half-life in the circulating blood, allowing it to accumulate to sufficient levels in tumor tissues. Moreover, even if sufficient amounts of ADCs can reach tumors by exploiting enhanced permeability and retention (EPR) effects [5] , the uneven distribution of ADCs in tumor tissues can results in unsatisfactory efficacy [6] . Most ADCs with stable linkers are designed to bind to cancer cells and be internalized, and then release the agents in cytoplasm [4] . In general, such ADCs exert their antitumor effects only after binding to the surface of cancer cells. Therefore, ADC distribution directly influences the antitumor effect, and this parameter must be improved in order to develop highly potent ADCs.
Uneven distribution of ADCs can arise due to several factors, including characteristics of mAb, the properties of the antigen, and other features of the tumor environment [6] . The characteristics of mAbs that are related to the distribution of ADCs include binding kinetics parameters, specificity, and molecular size [7] [8] [9] [10] [11] [12] , whereas relevant antigen properties include expression level, distribution, heterogeneity, and degradation rate of the targeted antigen in tumors [6, [12] [13] [14] . In regard to the tumor environment, interstitial fluid pressure, vascular permeability, and the stromal barrier are important influences on ADC distribution [8, [15] [16] [17] . Thus, uneven distribution of ADCs could result from complex interactions of these factors in solid tumor tissues.
Therefore, from the standpoint of ADC design, the optimization of mAb characteristics is essential for improving the distribution of ADCs.
In this study, we focused on the relationships between the binding kinetics parameters and antitumor effects of ADCs. Previous studies have already demonstrated the role of binding kinetics parameters on mAb distribution in tumor tissues [10, 12] , but have not specifically addressed ADCs. In order to predict the pharmacokinetics and pharmacodynamics of ADCs in vivo, mathematical simulation models have been developed that use binding kinetics parameters as one of several factors in their calculations [6, 14] . However, a direct comparison between the binding kinetics parameters of ADCs and their antitumor effects in the animal model is still necessary to elucidate the importance of binding kinetics parameters in ADC design.
Hence, we established three kinds of ADCs against tissue factor (TF) with different binding kinetics parameters. TF, a 47-kDa transmembrane glycoprotein that serves as an initiation factor for extrinsic blood coagulation, is highly expressed in various tumor tissues [18] . Consequently, TF is considered to be a promising target for cancer therapy using ADCs [19] [20] [21] . For construction of anti-TF ADCs, we adopted MMAE with the MC-vc-PABC linker, a widely used and highly potent combination [22] . We then investigated whether the binding kinetics parameters of anti-TF ADCs contributed to the distribution and antitumor effects in vivo.
Materials and methods

Antibodies and cell lines
Rat hybridoma clones producing anti-human TF mAbs were established previously [23] . None of the mAbs recognize mouse TF antigens. The human pancreatic cancer cell lines AsPC-3, PSN-1, and BxPC3 were obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA). The three cell lines were grown in RPMI-1640 medium (Wako, Osaka, Japan) supplemented with 10% fetal bovine serum (FBS, Thermo Fisher Scientific, Waltham, MA, USA), 100 units/mL of penicillin G, 100 μg/mL of streptomycin, and 0.25 μg/mL of amphotericin B (Wako) in a 5% CO 2 atmosphere at 37°C.
Generation of ADCs
Monomethyl auristatin E (MMAE) and a protease-cleavable linker based on maleimidocaproyl-valine-citrulline-p-amino-benzoyloxycarbonyl (MC-vc-PABC) were synthesized as previously described [21] . Anti-TF ADCs were constructed using a common protocol [22] . Mab clones 372, 444, 1084, and 1849 were reduced at 37°C for 30 min with 5.8, 5.2, 6.4, or 6.5 mM cysteamine hydrochloride (Sigma Aldrich, St. Louis, MO, USA), respectively, in the presence of 5 mM ethylenediaminetetraacetic acid (EDTA, Sigma Aldrich). The buffer was then replaced with DPBS (Thermo Fisher Scientific) containing 5 mM EDTA by ultrafiltration through a Vivaspin Turbo15 (Sartorius, Gottingen, Germany). Concentrations of free thiols were determined using 5,5′-dithiobis (2-nitrobenzoic acid) (Sigma Aldrich). Each reduced mAb was incubated at 4°C overnight with three equivalents of linker-MMAE per equivalent of free thiol. The buffer solutions were replaced with DPBS to completely remove free linker-MMAE. Finally, the concentrations of residual thiols were determined, and drug-antibody ratios (DARs) were calculated by comparing the concentrations of free and residual thiols. ADCs were then adjusted to the desired concentration and stored at −80°C until use in experiments.
SDS-PAGE
SDS-PAGE was performed under non-reducing conditions. Each ADC was loaded (5 μg/lane) on a 4-15% gradient gel (Bio-Rad, Hercules, CA, USA). After staining with Coomassie Brilliant Blue R-250, the gels were scanned using ChemiDoc XRS+ (Bio-Rad).
ELISA
To evaluate the effects of reduction, we compared the affinity between each mAb clone and its corresponding ADC. Recombinant human TF (rhTF) antigens (extracellular domain) [23] were immobilized on C8 MaxiSorp 96-well plates (Thermo Fisher Scientific) at 4°C overnight. The wells were washed three times with Tris-buffered saline (TBS) containing 0.05% Tween 20 (TBS-T) and blocked with TBS containing 1% BSA at 4°C until use. Each sample (0.2 μg/mL) was applied to the wells and incubated for 30 min at RT. After the wells were washed with TBS-T, HRP-conjugated mouse anti-rat kappa antibody (Southern Biotechnology Associates, Birmingham, AL, USA), used as a secondary antibody, was applied at a dilution of 1:500. The wells were washed with TBS-T and incubated with 1-Step Slow TMB-ELISA Substrate Solution (100 μL/well, Thermo Fisher Scientific) for 3 min at RT. The reaction was stopped with 2 N sulfuric acid (100 μL/well, Wako). Absorbance was measured on a SpectraMax190 microplate reader (Molecular Devices, San Jose, CA, USA).
Surface Plasmon Resonance (SPR) analysis
Binding kinetics parameters were measured on a Biacore T200 (GE healthcare, Uppsala, Sweden) as previously described [24] . Briefly, rhTF antigens were diluted to 5 μg/mL in 10 mM sodium acetate buffer (pH 5.0) and immobilized on a CM5 sensor chip (GE healthcare) for 30 s. Each ADC, at several concentrations (320 and 160, 80, 40, 20 nM), was allowed to interact with the well of the sensor chip for 30 s, and dissociation time was monitored for 3600 s. DPBS was used as the running buffer. Kinetics were monitored in single-cycle kinetics mode as a robust measurement [25] , and apparent binding kinetics parameters were determined by bivalent analysis. We conducted the experiments three times for each ADC clone in order to obtain exact SPR data, and determined average kinetics value of each clone. All experiments passed quality assessments for a good fit.
Fluorescence labeling
Each anti-TF ADCs were labelled with Alexa Fluor 488 or Alexa Fluor 647 using the Alexa Fluor Protein Labeling Kit (Thermo Fisher Scientific).
Flow cytometry (FCM) analysis
EC 50 of anti-TF ADCs was measured based on FCM data as described previously [24] . Briefly, BxPC3 cells were harvested and suspended in DPBS containing 0.5% BSA and 2 mM EDTA (BE-PBS) at a density of 1 × 10 6 cells/mL. BxPC3 cells were incubated for 30 min on ice with each ADC at several concentrations. After washing with BE-PBS, BxPC3 cells were incubated for 30 min on ice with Alexa Fluor 647-conjugated goat anti-rat IgG (H + L) antibody (Thermo Fisher Scientific) at a dilution of 1:250. After washing with BE-PBS, 0.4 μL/mL propidium iodide (Thermo Fisher Scientific) was added. Median fluorescence intensity of cells was analyzed using a Guava easyCyte (Merck Millipore, MA) with the FlowJo analysis software (Tree Star Inc., Ashland, OR, USA). TF expression level of PSN-1, AsPC-1, and BxPC3 cells was also evaluated by FCM analysis using 1849mAb (2 μg/mL) and the secondary antibody described above (1:500).
Internalization assay
BxPC3 cells were seeded at a density of 5 × 10 4 cells/mL in 96-well optical-bottom black plates (Thermo Fisher Scientific) and incubated at 37°C overnight. Each Alexa Fluor 488-conjugated ADC (0.1 μM) was added and incubated at 37°C for 15 min or 1, 3, or 6 h. The wells were washed three times with culture medium at 4°C and incubated for 1 h at 4°C with 20 μg/mL anti-Alexa Fluor 488 Rabbit IgG Fraction (Thermo Fisher Scientific) in order to quench the fluorescence of the ADC on the cell membrane, but not in the cytoplasm. The wells were then washed with DPBS and fixed with 4% paraformaldehyde (PFA, Wako) in DPBS for 15 min at room temperature (RT). After washing with DPBS, the cells were stained with DAPI solution (1 μg/mL) for 5 min at RT. More than 300 cells were randomly selected in each well, and fluorescence intensity in the cytoplasm was measured on an ArrayScan VTI HCS Reader (Thermo Fisher Scientific). After incubation with each Alexa Fluor 488-conjugated ADC for 3 h, representative fluorescence images were also obtained on a BIOREVO BZ9000 microscope (Keyence, Japan); in this experiment, quenching with antiAlexa Fluor 488 Rabbit IgG Fraction was not performed.
Cytotoxicity
PSN-1, AsPC-1, and BxPC3 cells were seeded at 5 × 10 3 cells/well in 96-well plates (Corning, Corning, NY, USA), incubated at 37°C overnight, and treated with the indicated concentration of ADCs or free MMAE for 72 h at 37°C. Cell viabilities were determined using the Cell Counting Kit-8 (Dojindo, Kumamoto, Japan).
LC-MS/MS analysis
The enzymatic assay was conducted as previously described [26] . Cathepsin B (Sigma Aldrich) from human liver was activated by incubation at 40°C for 10 min in activation buffer containing 1.2 mM Lcysteine and 0.75 mM EDTA. Anti-TF ADCs were incubated at 37°C for 0, 1, 6, 24 or 72 h with 1.33 μg/mL activated cathepsin B and MMAF (as an internal standard for analysis) in 120 mM sodium acetate buffer (pH 6.0). After the reaction, the samples were placed on ice and mixed with LC-MS-grade acetonitrile (Thermo Fisher Scientific). The concentration of free MMAE was determined by using an API3200 liquid chromatography-tandem mass spectrometry (LC-MS/MS) system (AB SCIEX, Framingham, MA, USA) and a Synergi™ 4 μm Hydro RP 80 Å analytical column, (Torrance, CA, USA). The LC-MS/MS assay for MMAE quantitation was described previously [27] . The transitions 732.7/170.3 and 718.7/152.2 were monitored for MMAF and MMAE, respectively. The standard curve for quantitative determination of MMAE ranged between 0.1 nM and 100 nM.
Sandwich ELISA
Goat anti-rat antibody (Bethyl Laboratories, TX) in coating buffer (50 mM carbonate-bicarbonate, pH 9.6) was immobilized onto C8 MaxiSorp 96-well plates at 4°C overnight. The wells were washed three times with TBS-T and blocked with TBS containing 1% BSA at 4°C until use. Plasma samples were obtained from mice after single-dose intravenous injection of ADCs (5 mg/kg). Diluted ADC standards or plasma samples were applied to the wells and incubated for 30 min at RT. After washing with TBS-T, the wells were incubated for 30 min at RT with HRP-conjugated mouse anti-rat kappa antibody at a dilution of 1:3000. After washing with TBS-T, the plates were incubated with 1-
Step Slow TMB-ELISA Substrate Solution for 3 min at RT. Absorbance was measured by SpectraMax190.
Animal models
All animal procedures and experiments were conducted with the approval of the Committee for Animal Experimentation of the National Cancer Center, Japan. Experiments meet the ethical standards required by law and also comply with guidelines for the use of experimental animals in Japan. Four-week-old female BALB/c nude mice were purchased from Charles River Laboratories Japan. One week later, BxPC3 cells (1 × 10 6 ) were implanted subcutaneously in the right flank; the tumors were allowed to grow for use in treatment experiments. Tumor size was calculated using the formula volume = length × (width) 2 × 1/2. All mice were sacrificed when tumor sizes reached 2000 mm 3 or weight loss exceeded 20%.
Antitumor effects
Two treatment experiments were conducted. The first was started when tumor size reached approximately 200 mm 3 . The second was started when tumor size reached approximately 600 mm 3 . When tumors reached the desired sizes, mice were randomly grouped (n = 5) and treated intravenously with 5 mg/kg mAbs + 68 μg/kg MMAE (equivalent MMAE dose with 5 mg/kg ADC) or 5 mg/kg ADCs in 100 μL DPBS. All treatments were administered twice in a week for three weeks (six doses).
Distribution in tumor tissues
Mice bearing BxPC3 tumors were euthanized under the anesthesia 3 h after intravenous injection of ADC conjugated with Alexa Fluor 647 (300 μg/mouse). The protocol for immunofluorescence staining was described previously [24] . Briefly, tumors were removed from mice and embedded in Tissue Tec optimal cutting temperature compound (Sakura Finetek, Japan), and frozen at −80°C until use. Frozen sections were fixed with 4% PFA in DPBS for 15 min at RT and blocked with 5% skim milk in DPBS for 1 h at RT. The sections were incubated with 2 μg/ mL goat anti-mouse CD31 polyclonal antibody (Thermo Fisher Scientific) for 1 h at RT, and then with 4 μg/mL anti-goat polyclonal antibody conjugated with Alexa Fluor 555 (Thermo Fisher Scientific) for 1 h at RT. The sections were stained with DAPI solution and covered with Fluoromount-G. All fluorescence images were obtained under the same conditions using the VS120 Virtual Slide System (Olympus, Japan).
Statistical analysis
All data are shown as the mean ± standard deviation (SD). Antitumor effects were analyzed by one-way ANOVA using EZR software [28] . p < 0.05 was considered statistically significant.
Results
Preparation of anti-TF ADCs
We prepared several anti-TF monoclonal antibodies conjugated with MMAE via the MC-vc-PABC linker. Calculation of the concentration of free thiol residues revealed that the DARs of 372ADC, 444ADC, (Table 1) . SDS-PAGE to determine the molecular size of the anti-TF ADCs showed that all ADC clones yielded almost the same band patterns (Fig. 1A) . Despite having undergone chemical reduction, there was no change in affinity between mAbs and their corresponding ADCs for any of the clones, as determined by ELISA (Fig. 1B) . This observation also confirmed that 372ADC was appropriate for use as a control ADC in the subsequent experiments.
Binding kinetics parameters
SPR analysis was performed three times for each anti-TF ADC clone to evaluate the apparent binding kinetics parameters. The representative sensorgrams clearly revealed differences in their dissociation rates (Fig. 1C) : the relative values of k d were as follows: 1084ADC > 444ADC > 1849ADC (Table 1) . Specifically, the k d value of 1084ADC was 39.3 times higher than that of 1849ADC, indicating that 1084ADC dissociated from TF antigens is more easily than 1849ADC. On the other hand, relative values of k a were as follows 444ADC = 1849ADC > 1084ADC ( Table 1 ). The k a value of 444ADC was approximately 1.7 times higher than that of 1084ADC. Consequently, the order of the binding affinity constant (K D ) values, calculated from the k d /k a ratio, was as follows: 1084ADC > 444ADC > 1849ADC. Thus, among these ADCs, 1849ADC had the highest affinity for TF antigens, whereas 1084ADC had the lowest. In comparison with the k a values, the k d values made a larger contribution to the difference in the K D values.
Characterizations of anti-TF ADCs
We next performed FCM analysis to investigate TF expression levels in several pancreatic cancer cell lines (Fig. 2A) . The results revealed that BxPC3, PSN-1, and AsPC-1 had high, medium, and low TF-expression levels, respectively. Therefore, we mainly used BxPC3 cells for subsequent experiments. EC 50 values were also measured to confirm the affinity of anti-TF ADCs for BxPC3 cells. 444ADC, 1084ADC, and 1849ADC had almost the same affinity against BxPC3 cells, whereas 372ADC exhibited no measurable binding (Fig. 2B) . Internalization of 444ADC, 1084ADC, and 1849ADC into BxPC3 cells was confirmed visually (Fig. 2C) . There was no difference in internalization efficiency among three anti-TF ADCs at any time point during the observation (Fig. 2D) .
We then analyzed the release efficiency of MMAE from each anti-TF ADC in vitro using an LC-MS/MS system (Fig. 2E) . Under acidic conditions (pH 6.0) in the presence of cathepsin B at 37°C, all ADCs released MMAE as a function of incubation time. After 72 h of incubation, all ADCs had released approximately 75% of the MMAE.
To monitor the pharmacokinetic profile of anti-TF ADCs in vivo, we injected each ADC (5 mg/kg) into mice, and then measured the concentrations of anti-TF ADCs in plasma using the sandwich ELISA method (Fig. 2F) . The results revealed that all ADCs had almost the same plasma half-life in mice. In addition, we conducted WST-8 assays using PSN-1, AsPC-1, and BxPC3 cells to investigate the cytotoxicity of anti-TF ADCs in vitro (Fig. 2G-I) . The results showed that 444ADC, 1084ADC, and 1849ADC had almost the same cytotoxic effect on all Table 2 .
Antitumor effects
We examined the efficacy of anti-TF ADCs in vivo using a BxPC3 xenograft model. When the average BxPC3 tumor size reached 200 mm 3 , each ADC (5 mg/kg) was injected twice a week for 3 weeks (Fig. 3A) . As a control, each mAb mixed with MMAE (not conjugated) was also injected at an equivalent dosage. None of the mAbs mixed with MMAE inhibited tumor growth inhibition, indicating that the anti-TF mAbs that we prepared could not induce immune responses such as ADCC and CDC in vivo. 372ADC, which has no affinity against TF antigens, inhibited tumor growth in comparison with the other controls, but the effect was not statistically significant. 372ADC may have accumulated due to EPR effects and degraded by proteases in extracellular regions. On the other hand, 444ADC, 1084ADC, and 1849ADC significantly inhibited BxPC3 tumor growth to similar extents, suggesting that the in vivo antitumor effects of the three anti-TF ADCs were consistent with their characteristics (cell-binding affinity, internalization efficacy, release efficiency of MMAE, cytotoxicity, and half-life in plasma).
Subsequently, we conducted an in vivo study using same model and dose schedule to confirm the equivalence of antitumor effects among anti-TF ADCs when the average BxPC3 tumor size reached 600 mm 3 ( Fig. 3C) . In this study, 372ADC did not inhibition tumor growth. 444ADC, 1084ADC, and 1849ADC were still efficacious, but exhibited differences in the degree of tumor inhibition. Especially in the early phase of treatment, 1084ADC had the highest efficacy, and the differences between 1084ADC and 1849ADC were statistically significant (p < 0.05 at day 3, p < 0.01 at day 7). All experiments in BxPC3 xenograft models were conducted without induction of weight loss (< 20%), and the dose schedule was well tolerated (Fig. 3B, D) . After treatments with anti-TF ADCs, regrowth of BxPC3 tumors was observed in all groups.
Distribution in BxPC3 tumors
To determine why the differences in antitumor effects between 1084ADC and 1849ADC were observed only in large tumors, we investigated the distribution of ADCs in BxPC3 tumors (Fig. 4) . Immunofluorescence staining revealed that 1084ADC was distributed evenly in all BxPC3 tumors, confirming the efficient penetration of 1084ADC into the central region of the tumors. On the other hand, 1849ADC was mainly localized near blood vessels. Thus, 1084ADC had a greater ability to penetrate BxPC3 tumors than 1849ADC.
Discussion
In this study, we observed that 444ADC, 1084ADC, and 1849ADC had remarkable differences in binding kinetics parameters, especially in regard to k d values (Table 1) . However, these ADCs exhibited equivalent pharmacological characteristics, including cell-binding affinity, internalization efficiency, MMAE release efficiency, cytotoxicity against TF-positive cell lines, and half-life in plasma (Fig. 2, Table 2 ). Their equivalent antitumor effects were also evident in small BxPC3 tumors (Fig. 3A) . Unexpectedly, however, in large BxPC3 tumors, 1084ADC (with a high k d value) exhibited statistically higher antitumor effects than 1849ADC (with a low k d value) in the early stage after the treatment initiation (Fig. 3C) . Immunofluorescence staining revealed that 1084ADC was distributed throughout the entire tumor tissue, whereas 1849ADC localized only in the vicinity of tumor blood vessels (Fig. 4) . The results indicated that ADCs with higher k d values can distribute more efficiently within tumor tissues. This study is the first to demonstrate the relationship between binding kinetics parameters and in vivo efficacy of ADCs in the animal model.
The relationship between affinity and distribution of antibodies has been investigated and reviewed previously [7, [9] [10] [11] [12] . Although antibodies with high affinity can effectively accumulate in tumor tissues and keep to bind target cells, their distribution is limited due to the binding-site barrier, resulting in poor tumor penetration. On the other hand, antibodies with moderate or low affinity could accumulate less efficiently, but penetrate more effectively in comparison with antibodies with higher affinity. A minimum affinity of approximatelỹ 10 −7 M is necessary for sufficient accumulation in tumors [9] .
Therefore, an antibody with balanced affinity would be considered as a promising antibody drug, especially in the context of ADCs. Because most ADCs target antigens on the cancer cell surface, they must have both high internalization efficiency and tumor penetration ability in order to achieve high efficacy in vivo. In this study, 1849ADC was expected to have higher internalization efficiencies in BxPC3 cells than other ADCs because of its higher affinity. However, its internalization efficiency was similar to those of other ADCs. We anticipated that rapid turnover ratio of TF antigens might have contributed to this unexpected observation. Because TF is a trigger protein of blood coagulation, it must be turned over more rapidly than other surface antigens such as Her2 and EGFR [20] . Consequently, 1084ADC (with a high k d value) would be rapidly internalized into the cells before dissociation from the TF antigen. Importantly, tumor size affected the differences in antitumor activity between 1084ADC and 1849ADC. Because the number of antigens in tumor tissues must increase with tumor volume, the influence of the binding-site barrier is enhanced to a greater extent when treating larger tumors at a given dose schedule. Consequently, 1084ADC exhibited higher in vivo efficacy than 1849ADC only against large tumors. It is conceivable that human clinical solid tumors possess larger tumor size than mice xenograft tumors. Therefore, we believe that the penetration efficiency should be considered more seriously in clinical practice. Aside from tumor size, the differences of antitumor efficacy might vary according to the dosage schedule (e.g., injected quantity, injection frequency), characteristics of the targeted antigens (e.g. expression level, localization, heterogeneity, turnover ratio), and tumor microenvironment (e.g., stroma formation, density, and permeability of tumor blood vessels) [6, 29, 30] . These complex factors should be investigated precisely in each patient, in order to select the optimal ADCs among various clones targeting the same antigen. These efforts may enhance the potential of ADCs.
Furthermore, recent studies indicate that the ADC linker (e.g. Val- R. Tsumura et al.
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Cit) has a possibility to be cleaved in extracellular regions by secreted proteases or other environmental factors [31] . Therefore, the further investigation for the distribution of both ADCs and payloads (e.g. MMAE) is necessary to definitely understand the effects of the distribution and the K d value of ADCs in vivo.
Taken together, our observations show that ADCs with higher affinity do not always exert higher antitumor activity. For the design of ADCs, researchers have paid more attention to the linker technology and the anticancer agent to be conjugated to date. However, various factors including the binding parameters of ADCs, the status of the targeted antigen, tumor vascular density, and tumor size should also be considered carefully.
Conclusion
We demonstrated that the k d value of ADCs can affect in vivo efficacy. Consequently, binding kinetics parameters should be considered when selecting an antibody for ADC design, depending on the property of the tumors to be targeted. To develop this strategy for future clinical use, elaborate experiments should be performed using in vivo models that faithfully recapitulate features of human cancer in terms of the biochemical characteristics of the mAb, target antigen, and tumor microenvironment.
